The company plans to raise funds by way of a share placement.
() has been granted a trading halt by the ASX pending the release of information regarding a share placement.
The company’s shares will remain halted until the earlier of, the release of relevant information, or, the commencement of trading next Tuesday.
Pharmaxis is an established pharmaceutical research company working on new therapies to treat inflammatory and fibrotic diseases.
This includes liver disease NASH, pulmonary fibrosis, kidney and liver fibrosis, inflammatory bowel diseases and cancer.
The company finished the June quarter with just over $31 million in cash.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE